Abstract:Abstract Background Risankizumab (RIS) is a humanized monoclonal antibody that inhibits interleukin-23 by binding to its p19 subunit. The use of RIS in the treatment of moderate to severe Crohn’s Disease (CD) was approved in December 2022. Intestinal ultrasound (IUS) is an accurate and well-tolerated modality for evaluating response to therapy. Here, we assessed the IUS response at 3 and 6 months following RIS therapy. Methods CD patients initiating RIS were recruited and evaluated by IUS at baseline (within 14 days of initiation), 3, and 6 months. Data elements collected at baseline included demographics, medication exposures, surgical history, as well as inflammatory biomarkers. IUS response (decrease in bowel wall thickness (BWT) ≥ 25%)) and transmural remission (TR) (normalization of BWT normalization, color doppler signal (CDS, modified Limberg (ML) score 0), wall stratification, inflammatory fat)) for each segment were evaluated. Paired t-tests were used to compare values at 3 and 6 months relative to baseline. Results A total of thirty-three (20, 60.6% female) patients were recruited; 30 completed baseline and 3 month IUS, while 18 patients have also completed a 6 month IUS. Median age was 55 years (IQR 39-63), with a 12 year median CD duration (IQR 5-28). Five had inflammatory behaviour, 19 had stricturing, and 6 had fistulizing behaviour. CD distribution was 18 ileal, 1 colonic, and 11 ileocolonic. Baseline mean CRP (4.1 ± 4.9 mg/L) did not differ at 3 months (5.0 ± 6.8 mg/L, p=0.16), nor at 6 months for patients with values available (6.2mg/L ± 8.3, p = 0.38). Of patients with FC concentrations, 3 month mean FC (129.4 ±70 mcg/g) (9 patients) had significantly decreased from baseline (427.6 ± 271 mcg/g) (p=0.008), and similarly at 6 months (9 patients; baseline 396 ± 299 vs. 129 ± 75, p = 0.02). 80.0% (4/5) patients with colonic BWT > 3mm had IUS response (baseline mean BWT 5.6±1.4mm vs 3.5 ± 0.8mm at 3 months (p=0.011). IUS response was achieved in 20% (5/25) with ileal CD at 3 months (BWT 6.3 ± 2.1mm vs 3 month 6.0 ± 2.5mm (p=0.31). 21.4% (3/14) of ileal CD patients had an IUS response at 6 months. There was a non-significant ileal BWT reduction (5.4 ± 1.6mm) from baseline (6.0 ± 1.7mm) at 6 months. Of the 9 with moderate to severe CDS, 55% (5/9) had reduction to mild CDS by 3 months. TR was achieved by one patient with ileal CD at 6 months. Conclusion IUS response was achieved in 80.0% of CD patients with colonic disease at 3 months follow RIS initiation. IUS response was detected for 20% of ileal CD patients at 3 months and 21.4% at 6 months A significant FC reduction by 3 and 6 months was attained. Further prospective patient recruitment and IUS at 6 and 12 months to assess preliminary results and longer-term response is needed.

An evaluation of risankizumab for the treatment of moderate-to-severe ulcerative colitis

OP25 Patients with Moderate to Severe Crohn’s Disease with and Without Prior Biologic Failure Demonstrate Improved Endoscopic Outcomes with Risankizumab: Results from Phase 3 Induction and Maintenance Trials

OP06 Risankizumab Maintenance Therapy in Patients With Moderately to Severely Active Ulcerative Colitis: Efficacy and Safety in the Randomised Phase 3 COMMAND Study

P1018 Population pharmacokinetic and exposure-response analyses for efficacy and safety of risankizumab in subjects with moderately to severely active Ulcerative Colitis

S1156 A Multi-Center Study of the Outcomes of Risankizumab Use Stratified by Prior Ustekinumab Exposure in Patients With Crohn's Disease: A Real-World Experience

Risankizumab Versus Ustekinumab for Moderate-to-Severe Crohn’s Disease

P593 Efficacy of Risankizumab in Patients With Moderately to Severely Active Ulcerative Colitis by Prior Advanced Therapy Failure and Mechanism of Action: Post Hoc Analysis of the INSPIRE and COMMAND Phase 3 Studies

Maintenance Risankizumab Sustains Induction Response in Patients with Crohn's Disease in a Randomized Phase 3 Trial.

Efficacy and Safety of Risankizumab for Crohn's Disease in Patients from Asian Countries: a Post Hoc Subanalysis of the Global Phase 3 ADVANCE, MOTIVATE, and FORTIFY Studies.

Risankizumab: Mechanism of action, clinical and translational science

S1472 Efficacy of Risankizumab Maintenance Therapy by Clinical Remission and Endoscopic Improvement Status in Patients With Moderately to Severely Active Ulcerative Colitis: Post Hoc Analysis of the COMMAND Phase 3 Study

S3892 Risankizumab Effectiveness in Perianal Crohn's Disease: A Single Tertiary Care Center Case Series

P745 Assessment of Crohn’s disease patients following risankizumab initiation using intestinal ultrasound: A prospective study

P741 Characterisation of endoscopic improvements with risankizumab treatment in patients with moderately to severely active Crohn’s disease

A drug safety evaluation of risankizumab for psoriasis

P862 Effects of induction and maintenance therapy with risankizumab on health-related quality of life outcomes in patients with moderately to severely active ulcerative colitis: A post-hoc analysis of Phase 2b/3 trials

P848 Risankizumab Effectiveness in Ustekinumab-naïve and Ustekinumab-experienced Patients with Crohn’s Disease- Real-world Data from a Large Tertiary Center

Mirikizumab (Omvoh) for Ulcerative Colitis

S1198 Endoscopic Response to Risankizumab in Patients With Refractory Crohn's Disease Who Failed Ustekinumab - Real-World Experience

Long-Term Safety and Efficacy of Risankizumab Treatment in Patients with Crohn’s Disease: Results from the Phase 2 Open-Label Extension Study

Matching-Adjusted Indirect Comparison Between Risankizumab and Ustekinumab for Induction and Maintenance Treatment of Moderately to Severely Active Crohn’s Disease